{
    "clinical_study": {
        "@rank": "124565", 
        "arm_group": [
            {
                "arm_group_label": "Adalimumab", 
                "arm_group_type": "Experimental", 
                "description": "receive adalimumab 40 mg eow  injections in combination with MTX for 24 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "receive placebo injections in combination with MTX for 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to compare longitudinally the effect of adalimumab plus methotrexate (MTX)\n      versus MTX monotherapy on cartilage GAG content, reflected by Delayed Gadolinium-enhanced\n      magnetic resonance imaging of cartilage (dGEMRIC) index, in patients with early progressive\n      rheumatoid arthritis (RA), who had not previously received any Disease modifying\n      antirheumatic drug (DMARD) or biologic treatment."
        }, 
        "brief_title": "The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in Early Rheumatoid Arthritis (RA) Patients", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be randomly assigned to either adalimumab q2w plus oral MTX qw combination\n      therapy or oral MTX qw monotherapy plus placebo subcutaneous (SC) q2w in a ration 2:1. To\n      maintain blinding, matching placebo SC injections will be dispensed q2w to the MTX\n      monotherapy group. All subjects will receive open-label MTX 15 mg qw as oral tablets. All\n      subjects will take approximately 5 mg weekly dietary supplement of oral folate throughout\n      the study on any day beginning 48 hours after ingestion of their oral study medication.\n      Defined as standard therapy oral folate supplementation will be taken in a single dose 24-48\n      h after MTX therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a diagnosis of early RA (ERA) fulfilling the 2010 American college of\n             rheumatology (ACR) criteria for classification of RA\n\n          -  Disease duration less than 12 months from symptoms onset.\n\n        Exclusion Criteria:\n\n          -  Subject has previous exposure to any systemic biologic therapy (e.g. abatacept,\n             tocilizumab) including anti-Tumor necrosis factor (TNF therapy) (e.g., infliximab,\n             golimumab, certolizumab pegol, etanercept) including adalimumab."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02150473", 
            "org_study_id": "CAR-ERA", 
            "secondary_id": "2013-004604-19"
        }, 
        "intervention": [
            {
                "arm_group_label": "Adalimumab", 
                "description": "adalimumab 40 mg every other week in combination with MTX for 24 weeks", 
                "intervention_name": "Adalimumab", 
                "intervention_type": "Drug", 
                "other_name": "Humira"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "rheumatoid Arthritis", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "ostendorf@med.uni-duesseldorf.de", 
                "last_name": "Benedikt Ostendorf, Prof.Dr.", 
                "phone": "4921181117817"
            }, 
            "facility": {
                "address": {
                    "city": "D\u00fcsseldorf", 
                    "country": "Germany", 
                    "state": "NRW", 
                    "zip": "40225"
                }, 
                "name": "Universit\u00e4tsklinikum D\u00fcsseldorf"
            }, 
            "investigator": {
                "last_name": "Benedikt Ostendorf, Prof.Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Delayed Gadolinium-enhanced Magnetic Resonance (MR) Imaging of Cartilage - A Pilot Study to Measure the Effect of Adalimumab Plus MTX Versus Placebo Plus MTX on Cartilage in Early RA Patients", 
        "overall_contact": {
            "email": "ostendorf@med.uni-duesseldorf.de", 
            "last_name": "Benedikt Ostendorf, Prof.Dr.", 
            "phone": "4902118117817"
        }, 
        "overall_official": {
            "affiliation": "Poliklinik f\u00fcr Rheumatologie", 
            "last_name": "Benedikt Ostendorf, Prof.Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Joint space narrowing will be measured by variable flip-angle imaging 3T MRI at week 24 and baseline. A possible reduction of the joint space narrowing should be seen by comparing mean intergroup difference of pooled (per patient) dGEMRIC index (T1 [ms]).", 
            "measure": "Joint space narrowing of the metacarpophalangeal (MCP II) and MCP III joints in the clinically dominant hand measured by variable flip-angle imaging 3 time (3T) MRI", 
            "safety_issue": "No", 
            "time_frame": "104 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02150473"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Heinrich-Heine University, Duesseldorf", 
        "sponsors": {
            "collaborator": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Heinrich-Heine University, Duesseldorf", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}